Bioxcel Therapeutics Inc

This study tested a new drug (BXCL701) combined with an immunotherapy (pembrolizumab) in 98 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the combination could shrink tumors or slow the disease. This is a disease control appr…

This completed study tested Igalmi, a fast-dissolving film placed under the tongue, for managing frequent agitation in people with schizophrenia or bipolar disorder. 29 adults received the drug as needed for 7 days in a clinic. Researchers looked for signs that the drug might sto…

This study tested a fast-dissolving film (BXCL501) placed under the tongue to quickly reduce agitation in people with bipolar disorder. About 380 adults with bipolar I or II who were very agitated took part. The goal was to see if the film safely calms agitation better than a pla…

This Phase 3 trial tested a sublingual film containing dexmedetomidine (BXCL501) to quickly reduce agitation in 380 adults with schizophrenia or related disorders. Participants received either the drug or a placebo film, and researchers measured changes in agitation symptoms over…

This study tested a sublingual film containing dexmedetomidine (BXCL501) to quickly calm agitation in 100 older adults with dementia. Participants received either the drug or a placebo, and researchers measured changes in agitation scores and side effects. The goal was to find a …

This study tested a new medicine called BXCL501 to see if it can safely reduce the unpleasant symptoms people feel when they stop taking opioids. 225 adults with opioid use disorder took part. The medicine was given as a film under the tongue, and researchers measured withdrawal …

This study tested a medicine called BXCL501 for calming sudden episodes of agitation in people with dementia. It involved 151 participants who took the medicine only when needed over 12 weeks. The goal was to see if it safely reduces severe restlessness, tension, or aggression.

This study tested an investigational medication called BXCL501 (dexmedetomidine) given as a film under the tongue for episodes of agitation in people with schizophrenia, schizoaffective disorder, or bipolar disorder. The trial included 452 adults aged 18-75 and compared the drug …

This study looked at how well patients, their family members, and doctors agree when rating agitation episodes in people with bipolar disorder or schizophrenia. Thirty-three adults received a treatment called BXCL501, and researchers compared different questionnaires to see which…